TuHURA Biosciences Inc. Common Stock (HURA)

FairStock Score: 30/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that produce cash and possess a durable competitive advantage. TuHURA is a clinical-stage immuno-oncology company with 22 employees and no reported revenue. In fiscal 2025, the year ended 2025-12-31, it lost $30.1 million, or $0.63 per diluted share. In fiscal Q2 2026, the quarter ended 2026-06-30, the net loss was $9.2 million, or $0.14 per diluted share. Trailing free cash flow was negative $29.9 million, and the FairStock-calculated FCF yield was negative 25.9%. Those are not the marks of a mature, self-funding business. The FairStock-calculated P/B is 6.24 at the 2026-10-13 close of $1.81, while the P/E is negative 3.35 and not meaningful without profits. The balance sheet shows debt-to-equity of 0.50, but the FairStock Piotroski F-Score is 0/9 and the Altman Z-Score is -2.03, which point to weak financial strength and distress risk. The Peter Lynch category is none because the company lost money in each of the last four years. The entire thesis rests on IFx-2.0, an innate immune agonist in a Phase 3 registration trial as an adjunctive therapy to Keytruda, plus Delta receptor technology. That is a binary scientific bet, not a proven moat. Graham would want a margin of safety in assets or earnings; here there is little of either. Buffett would ask for durable economics; those are absent today. I would watch cash burn, trial data, and financing needs. Until the company can show revenue or a clear path to profitability, the stock looks speculative, not cheap.

In plain English: TuHURA is a small company trying to develop experimental cancer medicines, with no product sales and only 22 employees. It has been losing money and burning cash, so the business looks weak based on its current financial numbers. At $1.81 a share, the price looks expensive compared with those numbers because the company has no profits and its value depends mostly on whether its main drug succeeds in testing.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2022 10-K (period ended 2022-06-30) · FY2021 10-K (period ended 2021-06-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer